Navigation Links
Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
Date:5/8/2012

PHILADELPHIA, May 8, 2012 /PRNewswire/ -- Today, H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Global Research & Development Center Inc., U.S., presented data which demonstrated significant improvements in overall symptoms of depression in elderly patients taking Lu AA21004, an investigational compound for the treatment of major depressive disorder (MDD). This study was presented at the 2012 American Psychiatric Association (APA) Annual Meeting in Philadelphia.

According to study results, elderly patients taking Lu AA21004 5mg/day showed a significantly greater (p=0.0011) improvement on the primary efficacy endpoint HAM-D24 total score versus placebo at Week 8 (mean difference to placebo of 3.3 points on the HAM-D24). Rates of HAM-D24 response (defined as a 50% or greater drop in HAM-D24 total score from baseline) were 53.2% versus 35.2% and rates of HAM-D17 remission (defined as a HAM-D17 total score less than or equal to 7) were 29.2% versus 19.3% at endpoint which were higher for Lu AA21004 than for placebo.

The study also included exploratory secondary endpoints evaluating select aspects of cognitive function. Patients on Lu AA21004 exhibited improvements from baseline compared to placebo on both, the Digit Symbol Substitution Test (DSST), a measure of processing speed, visuo-spatial attention, executive function and working memory, and the Rey Auditory Verbal Learning Task (RAVLT), a measure of verbal learning, including recall and recognition. 

"Depression is a multi-factorial disease where patients present with a variety of symptoms," said Anders Gersel Pedersen, Executive Vice President and Head of Research & Development at Lundbeck. "Having treatments to address the heterogeneity of the disease – given that the experience of depression varies so greatly from one patient to the next – is critically important to this patient population.  We are pleased that we are helping to b
'/>"/>

SOURCE H. Lundbeck A/S; Takeda Global Research & Development Center, Inc., U.S.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Hologic, Inc. (Hologic or the Company) (NASDAQ: ... and supplier of premium diagnostics, medical imaging systems ... the healthcare needs of women, today announced that ... clinical practice comparing breast cancer screening with Hologic,s ... mammography alone showed a significant reduction in recall ...
(Date:5/23/2013)... 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), the ... on the FDA panel meeting for non-thermal shortwave diathermy: ... Pulsed Shortwave Therapy Meeting was held on May 21, ... The focus of the meeting was very narrow, in ... solely on the application of non-thermal shortwave diathermy for ...
(Date:5/23/2013)... YORK , May 23, 2013  Intercept Pharmaceuticals, ... stage biopharmaceutical company focused on the development and commercialization ... diseases, such as primary biliary cirrhosis, today announced that ... Chief Executive Officer, will present at the Deutsche Bank ... Boston on Wednesday, May 29, 2013 at ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... Significant Improvement in Cognitive Performance and Global Clinical Status ... ... 30 Forest Laboratories, Inc.,(NYSE: FRX ) presented today positive ... at the 2008,Alzheimer,s Association International Conference on Alzheimer,s Disease,(ICAD). The study ...
... 30 Wound Care Innovations, LLC,a subsidiary of ... today an evidence based study with a NE ... wound care collagen,product, CellerateRx(R), on diabetic venous ulcers. ... Control and Prevention, diabetes now,affects nearly 24 million ...
Cached Medicine Technology:New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 2New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 3New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 4Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers 2
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... May 23 (HealthDay News) -- The sensation of itching ... traced back to a small molecule released in the ... mice. Researchers say this molecule, known as natriuretic ... the central nervous system. Ultimately, this signal is experienced ... and mice are similar, the researchers concluded that a ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) ... sharply, especially among Hispanic teens, according to a new government ... 15 to 19 dropped by nearly one half from 1991 ... teens to 31 births for every 1,000. From 2007 ... 25 percent, from 41.5 to about 31. During that ...
(Date:5/23/2013)... A shortage of a critical tuberculosis drug has hampered ... to contain the spread of the highly infectious lung ... was first used in 1951 and is one of ... first-line treatment for tuberculosis (TB). Patients must take the ... U.S. Centers for Disease Control and Prevention. However, ...
(Date:5/23/2013)... U.S. scientists have used virus isolated from a person ... whether the virus could infect and be transmitted between ... in influenza research, and efficient transmission of influenza virus ... the same process might occur in people. The research ... Allergy and Infectious Diseases, part of the National Institutes ...
Breaking Medicine News(10 mins):Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Ferrets, pigs susceptible to H7N9 avian influenza virus 2
... the No. 1 line-item cost of Medicare reimbursement and affects ... which can have devastating effects on the eye, affect 42 ... 80, and 68 percent of the population over the age ... University of Missouri professor has identified an important step in ...
... As millions of emails by,faithful Christians circulate around ... weeping image of Jesus Christ at Florida Hospital,s ... an explanation,today: "Jesus was weeping at the deplorable ... billion-dollar religious hospital,operation run by millionaire executives that ...
... effectiveness , , THURSDAY, April 17 (HealthDay News) -- The ... cells to their more plastic youthful condition in animal ... a possible new explanation for the antidepressant activity of ... it could be used to treat other conditions caused ...
... Dr. Thomas Gamba of Philadelphia to continue PDA,s efforts to improve ... ... Pennsylvania Dental,Association (PDA) recently installed Dr. Thomas W. Gamba of Philadelphia as,its ... improving patient access to oral health services will continue,to be a major ...
... MD, DrPH, Anna Cheskis Gelman and Murray Charles Gelman ... the Mailman School of Public Health and professor of ... 2008 Distinguished Investigator Award from NARSAD, the world,s leading ... Susser was selected for a study on famine and ...
... Celebrate Exemplary Nurses Who Support Chicagoland,s Medically ... when Sally Lemke lost,her nursing job providing prenatal care ... felt like a super star. That,s because the week,before ... her commitment and,passion for community health nursing and named ...
Cached Medicine News:Health News:MU researchers find clue to cataract formation 2Health News:Weeping Image of Jesus at Florida Hospital Explained 2Health News:Prozac Makes Old Brain Cells Young 2Health News:Prozac Makes Old Brain Cells Young 3Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 2Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 3Health News:Ezra Susser, MD, DrPH, receives Distinguished Investigator Award from NARSAD 2Health News:Chicagoland Super Star Community and Public Health Nurses - Now Is Your Chance to Win $25,000 2Health News:Chicagoland Super Star Community and Public Health Nurses - Now Is Your Chance to Win $25,000 3
... the world leader in peel-away introducers. ... for permanent pacemaker and defibrillator lead ... implantation, and for temporary pacemaker insertions. ... Medical Peel-Away introducers includes the Di-Lock™ ...
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... Supreme and Response catheters comprise the ... available for electrophysiology procedures. Their advanced ... for superior torque response with a ... curves and French sizes, Supreme and ...
... Supreme and Response catheters comprise the ... available for electrophysiology procedures. Their advanced ... for superior torque response with a ... curves and French sizes, Supreme and ...
Medicine Products: